Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft;Tratamiento de inducción combinando inmunoglobulinas, plasmaféresis y rituximab en pacientes hipersensibilizados que reciben trasplante renal de cadáver

Nefrologia

Volumn 30, Issue 2, 2010, Pages 252-257

  Rufino Hernández, J Margarita ^a   Cabello Moya, E ^a   Gonzalez Posada J M ^a   Hernandez Marrero D ^b   Perez Tamajon L ^a   Marrero Miranda, D ^a   Garcia Rebollo S ^a   Martin Urcuyo B ^c   Rodriguez Hernandez A ^a   Franco Maside, A ^a   Barrios del Pino, Y ^a   Rodriguez Rodriguez R ^a   Maceira Cruz, B ^a   Torres Ramirez A ^a   Salido Ruiz, E ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL GENERAL DE LANZAROTE   (Spain)

Author keywords

Hypersensitive patients; Immunoglobulins; Plasmapheresis; Renal transplant; Rituximab

Indexed keywords

ALLOANTIBODY; DRUG DERIVATIVE; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ARTICLE; BLOOD; CADAVER; CASE REPORT; CHRONIC KIDNEY FAILURE; DONOR; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNIZATION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PLASMAPHERESIS; PREMEDICATION; REOPERATION;

ANTIBODIES, MONOCLONAL; CADAVER; COMBINED MODALITY THERAPY; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLASMAPHERESIS; PREDNISONE; PREMEDICATION; REOPERATION; TACROLIMUS; TISSUE DONORS;

EID: 77952300707     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Jan.10233     Document Type: Article

References (20)

1. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-62.
2. Jordan SC, Vo AA, Nast CC, Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Review. Clin Transpl 2003;193-8.
3. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications [review]. Am J Transplant 2003;6:653-64.
4. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-51.
5. Sivakumaran P, Vo AA, Villicana R, Peng A, Jordan SC, Pepkowitz SH, et al. Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts. Clin Apher 2009;24:155-60.
6. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-95.
7. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;2:346-51.
8. Medeiros M, Alberú J, García GR, Fuentes Y, Velasquez L. Polyoma virus in transplant recipients [review]. Nefrologia 2008;28:203-11.
9. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;4:753-60.
10. Ding R, Medeiros M, Dadhania D, Muthukumar T, Kracker D, Kong JM, et al. Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1 in urine. Transplantation 2002;74:987-94.
11. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004;78:772-4.
12. Fehr T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009;87:1837-41.
13. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004;4:996-1001.
14. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts [review]. Expert Opin Investig Drugs 2007;16:625-33.
15. Webster A, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients [review]. Cochrane Database Syst Rev 2006;2:CD004756.
16. Muro M, Llorente S, Gónzalez-Soriano MJ, Minguela A, Gimeno L, Álvarez-López MR. Pre-formed donor-specific alloantibodies (DSA) detected only by luminex technology using HLA-coated microspheres and causing acute humoral rejection and kidney graft dysfunction. Clin Transpl 2006;379-83.
17. Lee PC, Ozawa M. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Clin Transpl 2007;219-26.
18. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008;86:820-5.
19. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2009. Published Online: 28 Jul 2009.
20. Kumar D, Gourishankar S, Mueller T, Cockfield S, Weinkauf J, Vethanayagam D, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009;2:167-70.